Hubei Jumpcan Pharmaceutical Co., LtdSSE: 600566

(600566)"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Self-exercise Results in Q3 2026 under the 2022 Restricted Share and Stock Option Incentive Plan and Changes in Share Capital

· Issued by Hubei Jumpcan Pharmaceutical Co., Ltd via Shanghai Stock Exchange

Filed with SSE · Stock code 600566 · · 5 pages · Chinese

Summary by 6ix AI

The announcement details the number of shares exercised and the impact on the company's capital structure, confirming that the first exercise period has been fully completed. It also outlines the listing arrangements for the exercised shares and the restrictions on transfer for directors and senior management. The filing concludes that the exercise of these shares will not have a significant impact on the company's financial status or operating results.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600566hubei-jumpcan-pharmaceutical-co-ltdannouncement-on-self-exercise-results-in-q3-2026-under-the-2022-restricted-share-and-stock-option-incentive-plan-and-changes-in-share-capital

Release

Announcement on Self-exercise Results in Q3 2026 under the 2022 Restricted Share and Stock Option Incentive Plan and Changes in Share Capital

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Hubei Jumpcan Pharmaceutical Co., Ltd on 6ix

Story so far

Earlier from Hubei Jumpcan Pharmaceutical

Later from Hubei Jumpcan Pharmaceutical

All Hubei Jumpcan Pharmaceutical news releases